Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;25(1):2408042.
doi: 10.1080/15384047.2024.2408042. Epub 2024 Sep 28.

Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling

Jianjun Wang  1 , Qifan Jia  2 , Jingyao Sun  2 , Sen Wu  1 , Li Wei  1 , Wenjian Yao  1
Affiliations

Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling

Jianjun Wang et al. Cancer Biol Ther. .

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is a primary histological type of esophageal carcinoma with high morbidity. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL) is a circadian clock gene associated with the progression of multiple tumors. However, its roles and mechanisms in ESCC remain unknown.

Methods: ARNTL expression was analyzed using TCGA database and detected using qRT-PCR, and ARNTL-related pathways were analyzed through GSEA. Cell functional behaviors were assessed in vitro by measuring cell viability, proliferation, and apoptosis. Cell growth in the murine model was investigated through xenograft model and immunofluorescence assays of PCNA and Ki67. The downstream targets of ARNTL were analyzed through sequencing and identified via luciferase report, ChIP, and RNA pull-down analyses. Dual-specificity protein phosphatase-1 (DUSP1) expression was analyzed using GEO datasets and measured using qRT-PCR and western blotting. Protein expression was examined via western blotting.

Results: ARNTL expression was decreased in esophageal carcinoma and associated with histological types, and elevated expression of ARNTL repressed ESCC cell viability and proliferation and facilitated cell apoptosis. ARNTL upregulation reduced tumor cell growth in murine models and decreased PCNA and Ki67 levels. Furthermore, DUSP1 was downregulated upon ARNTL silencing in ESCC. ARNTL could bind and positively regulate DUSP1 transcription. Additionally, DUSP1 silencing reversed the influences of ARNTL upregulation on cell viability, proliferation, and apoptosis in ESCC cells. ARNTL attenuated the activation of the ERK signaling by decreasing ERK phosphorylation through upregulation of DUSP1.

Conclusion: ARNTL hinders cell growth and contributes to cell apoptosis by inactivating ERK signaling through transcriptional upregulation of DUSP1 in ESCC.

Keywords: ARNTL; DUSP1; ERK; Esophageal squamous cell carcinoma; apoptosis.

Plain language summary

• ARNTL is differentially expressed in ESCC and associated with cell apoptosis.• ARNTL augments cell apoptosis.• ARNTL increases DUSP1 transcription.• ARNTL inhibits activation of the ERK signaling by upregulating DUSP1.• DUSP1 silencing reverses the effects of ARNTL in esophageal squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
ARNTL is differentially expressed in ESCC.
Figure 2.
Figure 2.
ARNTL upregulation hinders cell growth and promotes cell apoptosis in ESCC.
Figure 3.
Figure 3.
ARNTL upregulation reduces ESCC cell growth in murine model.
Figure 4.
Figure 4.
The potential targets of ARNTL.
Figure 5.
Figure 5.
ARNTL regulates DUSP1 transcription.
Figure 6.
Figure 6.
DUSP1 knockdown reverses the effect of ARNTL upregulation on cell growth in ESCC cells.
Figure 7.
Figure 7.
DUSP1 knockdown reverses the effect of ARNTL upregulation on cell apoptosis in ESCC cells.
Figure 8.
Figure 8.
ARNTL upregulation blocks activation of the ERK signaling by upregulating DUSP1.
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–14. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Chen Y, Yu R, Liu Y. Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma. Crit Rev Oncol Hematol. 2023;190:104115. doi: 10.1016/j.critrevonc.2023.104115. - DOI - PubMed
    1. Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789. doi: 10.1016/j.esmoop.2023.100789. - DOI - PMC - PubMed
    1. Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol. 2020;10:1727. doi: 10.3389/fonc.2020.01727. - DOI - PMC - PubMed
    1. Dong Z, Zhang H, Zhan T, Xu S. Integrated analysis of differentially expressed genes in esophageal squamous cell carcinoma using bioinformatics. Neoplasma. 2018;65(4):523–531. doi: 10.4149/neo_2018_170708N470. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources